Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration - PubMed (original) (raw)
Case Reports
. 2004 Oct;130(10):623-5.
doi: 10.1007/s00432-004-0593-4. Epub 2004 Jul 28.
Affiliations
- PMID: 15449188
- DOI: 10.1007/s00432-004-0593-4
Case Reports
Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration
Evangelos Terpos et al. J Cancer Res Clin Oncol. 2004 Oct.
Abstract
Bortezomib (VELCADE) is a proteasome inhibitor, which has been recently used for the treatment of relapsed/refractory multiple myeloma (MM) with encouraging results. Tumour lysis syndrome (TLS) has been described during chemotherapy for many haematological malignancies, such as acute lymphoblastic leukaemia and high-grade lymphomas. TLS is very rare in MM with ten reported cases, including approximately 1% of patients receiving high-dose chemotherapy with stem cell support (ASCT). We report here a patient with refractory MM and deletion 13q, who had received more than four lines of previous treatment, including two ASCT, and had relapsed. The patient received bortezomib, as a single agent, at a dose of 1.3 mg/m(2) twice per week for 2 weeks, in a 3-week cycle, and developed TLS after the second dose of cycle one. Bortezomib therapy, due to the rapidity of its action, may result in TLS in myeloma patients who have rapidly proliferative disease with a high tumour burden. Therefore, TLS should be looked for during the first cycle of bortezomib treatment and suitable precautions should be considered.
Similar articles
- Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia.
Jaskiewicz AD, Herrington JD, Wong L. Jaskiewicz AD, et al. Pharmacotherapy. 2005 Dec;25(12):1820-5. doi: 10.1592/phco.2005.25.12.1820. Pharmacotherapy. 2005. PMID: 16305302 - Rapid progression of anemia related to tumor-lysis syndrome associated with bortezomib treatment in myeloma patients.
Suzuki K, Terui Y, Nishimura N, Ueda K, Mishima Y, Sakajiri S, Yokoyama M, Aiba K, Hatake K. Suzuki K, et al. Jpn J Clin Oncol. 2014 May;44(5):435-41. doi: 10.1093/jjco/hyu017. Epub 2014 Mar 23. Jpn J Clin Oncol. 2014. PMID: 24664944 - [Multiple myeloma complicated with disseminated zygomycosis after bortezomib therapy].
Nakamura S, Yata K, Jinno T, Harada T, Fujii S, Miki H, Nakano A, Kagawa K, Takeuchi K, Ozaki S, Abe M, Matsumoto T. Nakamura S, et al. Rinsho Ketsueki. 2010 Aug;51(8):690-5. Rinsho Ketsueki. 2010. PMID: 20805677 Japanese. - Bortezomib in multiple myeloma.
Mateos MV, San Miguel JF. Mateos MV, et al. Best Pract Res Clin Haematol. 2007 Dec;20(4):701-15. doi: 10.1016/j.beha.2007.09.003. Best Pract Res Clin Haematol. 2007. PMID: 18070714 Review. - Pharmacology, pharmacokinetics, and practical applications of bortezomib.
Schwartz R, Davidson T. Schwartz R, et al. Oncology (Williston Park). 2004 Dec;18(14 Suppl 11):14-21. Oncology (Williston Park). 2004. PMID: 15688598 Review.
Cited by
- Management of nephrotoxicity of chemotherapy and targeted agents: 2020.
Chiruvella V, Annamaraju P, Guddati AK. Chiruvella V, et al. Am J Cancer Res. 2020 Dec 1;10(12):4151-4164. eCollection 2020. Am J Cancer Res. 2020. PMID: 33414992 Free PMC article. Review. - Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study.
Kondo M, Hotta Y, Yamauchi K, Sanagawa A, Komatsu H, Iida S, Kimura K. Kondo M, et al. BMC Cancer. 2020 Nov 17;20(1):1117. doi: 10.1186/s12885-020-07592-9. BMC Cancer. 2020. PMID: 33203424 Free PMC article. - Tumor Lysis Syndrome in Patients with Hematological Malignancies.
Belay Y, Yirdaw K, Enawgaw B. Belay Y, et al. J Oncol. 2017;2017:9684909. doi: 10.1155/2017/9684909. Epub 2017 Nov 2. J Oncol. 2017. PMID: 29230244 Free PMC article. Review. - Tumor Lysis Syndrome in Multiple Myeloma: An Increasingly Recognized Risk-A Report of Seven Cases.
Singh A, Gupta S, Yim B, Thekkekara R. Singh A, et al. Indian J Hematol Blood Transfus. 2017 Mar;33(1):41-44. doi: 10.1007/s12288-016-0731-6. Epub 2016 Oct 3. Indian J Hematol Blood Transfus. 2017. PMID: 28194054 Free PMC article. - Tumor lysis syndrome in multiple myeloma treated with bortezomib.
Dhanraj KM, Biswajit D. Dhanraj KM, et al. J Pharmacol Pharmacother. 2014 Apr;5(2):161-2. doi: 10.4103/0976-500X.130091. J Pharmacol Pharmacother. 2014. PMID: 24799821 Free PMC article.
References
- Oncogene. 2003 Nov 20;22(52):8386-93 - PubMed
- Oncologist. 2003;8(6):508-13 - PubMed
- Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9 - PubMed
- Br J Haematol. 1999 Jun;105(4):938-41 - PubMed
- Semin Hematol. 2001 Oct;38(4 Suppl 10):4-8 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical